Fluocortin has been studied as a corticosteroid for treatment of dermatitis and eczema Spain A174817.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Fluocortin. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocortin. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluocortin. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluocortin. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluocortin. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluocortin. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Fluocortin. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluocortin. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fluocortin. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluocortin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Fluocortin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocortin. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocortin. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Fluocortin. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocortin. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocortin. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocortin. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocortin. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocortin. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocortin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocortin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocortin. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocortin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocortin. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocortin. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocortin. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocortin. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocortin. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluocortin. |
| Cladribine | Fluocortin may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocortin. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Fluocortin. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluocortin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fluocortin. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluocortin. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluocortin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocortin. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Fluocortin. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Fluocortin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluocortin. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Fluocortin. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocortin. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Fluocortin. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluocortin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluocortin. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Fluocortin. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Fluocortin. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluocortin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fluocortin. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fluocortin. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Fluocortin. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Fluocortin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocortin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Fluocortin. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Fluocortin. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocortin. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocortin. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Fluocortin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Fluocortin. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluocortin. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Fluocortin. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Fluocortin. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Fluocortin. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluocortin. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Fluocortin. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluocortin. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluocortin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Fluocortin. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Fluocortin. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with Fluocortin. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fluocortin. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Fluocortin. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Fluocortin. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Fluocortin. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Fluocortin. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluocortin. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluocortin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluocortin. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Fluocortin. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with Fluocortin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Fluocortin. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Fluocortin. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocortin. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Fluocortin. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Fluocortin. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluocortin. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Fluocortin. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Fluocortin. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Fluocortin. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Fluocortin. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Fluocortin. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluocortin. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Fluocortin. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Ifosfamide is combined with Fluocortin. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Fluocortin. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Fluocortin. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Fluocortin. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Paclitaxel is combined with Fluocortin. |
| Docetaxel | The risk or severity of adverse effects can be increased when Docetaxel is combined with Fluocortin. |
| Dasatinib | The risk or severity of adverse effects can be increased when Dasatinib is combined with Fluocortin. |